Diabetes management, thyroid function, adrenal scoring, and calcium homeostasis.
Convert hemoglobin A1C to estimated average glucose (eAG).
Predicts risk of undiagnosed diabetes to determine who should be screened. Uses demographic and clinical factors to identify individuals at high risk for type 2 diabetes mellitus.
Estimates 5-year risk of developing type 2 diabetes in Australian patients based on demographic, lifestyle and simple anthropometric measures
Percent excess weight loss after bariatric surgery.
Calculates daily energy expenditure using the Harris-Benedict equation. Estimates the minimum daily caloric requirements at rest (basal metabolic rate) and can be adjusted for activity level to determine total daily energy needs.
Calculates the difference between bedtime and morning fasting blood glucose to guide prandial insulin therapy decisions in patients with type 2 diabetes
WHO interpretation of DXA T-scores.
Assesses beta cell secretory function in patients with diabetes/pre-diabetes. The C-peptide to glucose ratio (CGR) is a simple marker that helps evaluate endogenous insulin secretion capacity and can guide diabetes management decisions.
Calculates corrected calcium level for patients with hypoalbuminemia or hyperalbuminemia
Predicts risk of having previously undiagnosed type 2 diabetes based on clinical and demographic factors. Developed for population screening and identification of high-risk individuals who should undergo diabetes testing.
CANRISK screens for undiagnosed type 2 diabetes mellitus and prediabetes in Canadian adults aged 18-74 years. It was developed by the Canadian Task Force on Preventive Health Care in partnership with the Public Health Agency of Canada and has been validated in Canada's multi-ethnic population.
Assesses impaired awareness of hypoglycemia in diabetes.
Measures diabetes-related emotional distress across four domains to identify sources of distress and guide targeted interventions for patients with diabetes.
Predicts in-hospital mortality in patients with diabetic ketoacidosis using clinical and laboratory parameters at presentation, 12 hours, and 24 hours
ADA DKA severity classification.
Diagnoses familial hypercholesterolemia (FH) based on clinical, genetic, and family history using the Dutch Lipid Clinic Network (DLCN) point-based scoring system. Provides stratification into possible, probable, or definite FH categories.
Stratifies the presence and severity of obesity-related health impairments across medical, functional, and psychological domains to guide treatment decisions and predict outcomes.
Estimates average glucose level from Hemoglobin A1C value using the linear relationship established by the A1c-Derived Average Glucose (ADAG) Study Group.
Identifies patients at high risk for type 2 diabetes within 10 years without the need for laboratory tests
Standard titration schedules for GLP-1 RAs (educational reference).
Calculates the rate at which glucose is administered intravenously, particularly important in neonatal and pediatric care to maintain appropriate blood glucose levels. Used to monitor and adjust dextrose infusions to prevent hypoglycemia while avoiding excessive glucose administration.
Single-question screen for impaired awareness of hypoglycemia in diabetes: 'Do you know when your hypos are commencing?'
Approximates insulin resistance using fasting glucose and insulin levels. A simple, non-invasive method to quantify insulin resistance and beta-cell function.
Predicts 12-month risk of hypoglycemic episodes in Type 2 Diabetes Mellitus (T2DM) patients for population management and targeted interventions
Calculates I-131 activity for hyperthyroidism ablation from gland size, uptake and prescribed dose per gram.
Stratifies risk of fasting during Ramadan in diabetic patients using validated clinical parameters. The IDF-DAR tool provides evidence-based guidance for healthcare providers and patients to make informed decisions about the safety of fasting during Ramadan based on diabetes type, glycemic control, complications, and other risk factors.
Estimates glucose lowering per unit of bolus insulin from total daily dose (1800/1500 rule).
Full replacement levothyroxine dose 1.6 mcg/kg/day with safety cap.
Prognostic score for papillary thyroid carcinoma: Metastasis, Age, Completeness, Invasion, Size.
NCEP ATP III (2005 update) criteria for metabolic syndrome: ≥3 of 5 — elevated waist circumference, triglycerides ≥150 mg/dL, low HDL, BP ≥130/85 mmHg, fasting glucose ≥100 mg/dL (or treatment for each).
Predicts risk of type 2 diabetes in previously undiagnosed patients using fasting glucose, triglycerides, BMI, and HDL cholesterol. A simple, non-insulin dependent marker for insulin resistance.
Diagnostic scoring system for myxedema coma (MC), a rare but life-threatening decompensated state of extreme hypothyroidism. This validated scoring system facilitates early recognition and treatment by evaluating thermoregulatory, central nervous, cardiovascular, gastrointestinal, and metabolic dysfunction along with precipitating events.
Neuropathy Disability Score (NDS) for diabetic peripheral neuropathy: vibration, pinprick, and temperature sensation (0 normal/1 abnormal per foot) plus ankle reflex (0 normal/1 with reinforcement/2 absent per foot); total 0-10. 0-2 normal, 3-5 mild, 6-8 moderate, 9-10 severe.
Estimates whole-body fat percentage from height, waist and sex.
Weekly titration schedule: 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg.
Approximate dose equivalence between levothyroxine (T4) and liothyronine (T3) using the standard ~4:1 potency ratio (25 mcg T3 ≈ 100 mcg T4). For education and conversion planning when switching thyroid hormone preparations.
Estimates the full replacement dose of levothyroxine for primary hypothyroidism: approximately 1.6 mcg/kg/day based on body weight (ATA guidance). Capped at 300 mcg/day; elderly patients and those with cardiac disease should start lower and titrate.
University of Texas (Armstrong/Lavery) diabetic foot wound classification: wound grade 0-3 (depth) crossed with stage A-D (infection/ischemia). Higher grades and stages predict worse outcomes including amputation.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.